Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
ANNALS OF ONCOLOGY(2022)
Abstract
CheckMate 816 (NCT02998528), a phase 3 study, met its primary endpoints of statistically significant and clinically meaningful improvements in event-free survival and pathological complete response with neoadjuvant NIVO + chemo vs chemo for resectable NSCLC. We present HRQoL results from the neoadjuvant treatment period.
MoreTranslated text
Key words
lung cancer,nivolumab,chemotherapy,neoadjuvant treatment,platinum-doublet,non-small,health-related
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined